Year: 2022

SANTA CLARA, Calif., Dec. 30, 2022 (GLOBE NEWSWIRE) — Agora, Inc. (NASDAQ: API) (“Agora”), a pioneer and leading platform for real-time engagement APIs, today announced a change in its board of directors. Ms. Jenny Hong Wei Lee has tendered her voluntary resignation from Agora’s board of directors due to personal reasons, effective as of today. Mr. Steve Zhang has been appointed as a director on Agora’s board of directors and will serve as a member of the audit committee and compensation committee, effective as of today. Mr. Steve Zhang has over 30 years of experience in the global information technology industry and had served in senior executive roles at leading information technology firms in Asia and the United States. “On behalf of the board, we sincerely thank Jenny for her dedicated service and invaluable advice to our board...

SPU-21 effective in controlling arthritis progression.  SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide  ENGLEWOOD CLIFFS, NJ, Dec. 30, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. Silo Pharma is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).  In the most recent phase of this ongoing animal study, tests were conducted to evaluate the disease-suppressive effects of an SPU-21 peptide-guided anti-arthritis...

TORONTO, Dec. 30, 2022 (GLOBE NEWSWIRE) — Sparton Resources Inc. (TSXV.SRI) (“Sparton” or the “Company“) announced today that it has closed, effective December 30, 2022, the first tranche of a $500,000 private placement financing through the sale of 1,100,000 Flow Through Share Units (“the Units”) to a number of individual accredited investors (the “Investors”) for total proceeds of $88,000. Please see Sparton news release dated December 1, 2022. Each Unit consists of one common share of the Company priced at $0.08 and a one-half Share Purchase Warrant (“SPW”). Two SPWs will entitle the warrant holder to purchase one additional Sparton common share at a price of $0.12 until December 30, 2024. The placement was non-brokered and commissions and finder’s fees of 7% cash and 7% in SPWs may be payable on a portion...

TORONTO, Dec. 30, 2022 (GLOBE NEWSWIRE) — Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”) is pleased to provide a summary of the Company’s key accomplishments in 2022 to advance the Beartrack-Arnett Gold Project (“Beartrack-Arnett”) located in Idaho, USA. HighlightsBeartrack-Arnett Indicated Mineral Resources increased to 65.0 million tonnes at 1.01 g/t gold containing 2.11 million ounces of gold1, up 56% over the 2020 Indicated Mineral Resource2, and Inferred Mineral Resources increased to 46.2 million tonnes at 1.31 g/t gold containing 1.94 million ounces of gold1, up 19% over the 2020 Inferred Mineral Resource2 On the main Beartrack-Arnett trend of mineralization, four core drill holes were completed for 2,600 meters of drilling. Follow-up drilling at Joss continued to demonstrate the high-grade...

Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of potential partnership opportunities to advance the global AD Phase 3 program Progress of China pivotal AD trial remains on track with completion of 36-week Stage 2 expected in H2 2023 SAN DIEGO and TAICANG, SUZHOU, China, Dec. 30, 2022 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today provided a business update for its operations and clinical trial development programs. “We continue to have great confidence in our global development strategy, and particularly...

JERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products for the treatment of infectious and autoimmune diseases, today published a letter from its CEO, Amir Reichman, addressing 2022 accomplishments, successful preclinical trial results of the inhaled COVID-19 NanoAb therapy as well as recent financing activities to support 2023 objectives. The letter reads as follows:  Dear BiondVax Shareholders,  BiondVax’s 2022 achievements leave me incredibly optimistic about BiondVax’s growth potential and ability to deliver value to our stakeholders.  My optimism is based on our people, our partnerships and BiondVax’s remarkable turnaround. When I became CEO in 2021, I...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Dec. 30, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, announces an organizational change in Avicanna LATAM S.A.S. with Lucas Nosiglia stepping down as President of Avicanna LATAM S.A.S. effective January 31, 2023 and transitioning to another role within the Company. About Avicanna Inc. Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization...

HONG KONG, Dec. 30, 2022 (GLOBE NEWSWIRE) — Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online brokerage and wealth management platform, today makes the following announcement: Futu noted that the China Securities Regulatory Commission (the “CSRC”) posted an announcement on December 30, 2022 relating to the Company’s cross-border operations in mainland China. Futu will fully cooperate with the CSRC and take all necessary measures to review its cross-border operations in mainland China and to comply with all applicable rules and regulations. The Company will proactively seek guidance from and cooperate with the CSRC in connection with its efforts to ensure legal compliance of its business activities in mainland China. In the meantime, the Company will continue to provide high-quality services...

December 30th, 2022, – Avenir LNG Limited and its subsidiaries (NOTC: AVENIR) (“Avenir” or the “Company or Group”), supplies small-scale LNG to off-grid industry, power generation and transport fuel sectors as well as providing infrastructure to support the development of LNG as a marine fuel, today announced its unaudited financial and operating results for the third quarter ended September 30, 2022. Peter Mackey, Chief Executive Officer of Avenir commented: “Avenir is pleased to report operating revenues of $20.9 million and EBITDA of $5.1 million for Q3 2022. This marks the 1st full quarter in our history with all of our assets in service, a significant milestone for the company. Global gas and LNG markets remained highly volatile throughout Q3 with the European gas benchmarking once again reaching extraordinarily high price levels....